Effects of Aldose Reductase Inhibitors on the Progression of Nerve Damage

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Diabetic Medicine

• Publication date

  1993-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1464-5491.1993.tb00194.xPMID 8334837
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Preventive effect of long-term aldose reductase inhibition (ponalrestat) on nerve conduction and sural nerve structure in the spontaneously diabetic Bio-Breeding rat.

  1990cited by this paper
• Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil.

  1988cited by this paper
• Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications.

  1987cited by this paper
• The effect of sorbinil treatment on red cell sorbitol levels and clinical and electrophysiological parameters of diabetic neuropathy

  1986cited by this paper
• Limited benefit of treatment of diabetic polyneuropathy with an aldose reductase inhibitor: a 24-week controlled trial

  1985cited by this paper
• Clinical and neurophysiological studies with the aldose reductase inhibitor, sorbinil, in symptomatic diabetic neuropathy

  1984cited by this paper

• Curious effects of fluorine on medicinally active compounds

  2021cites this paper
• Synthesis of new arylsulfonylspiroimidazolidine-2',4'-diones and study of their effect on stimulation of insulin release from MIN6 cell line, inhibition of human aldose reductase, sorbitol accumulations in various tissues and oxidative stress.

  2019cites this paper
• Diabetic Neuropathy: Current Status and Future Prospects

  2017cites this paper
• Strategic Incorporation of Fluorine for Drug Discovery and Development

  2017cites this paper
• Diabetic Polyneuropathy in Type 2 Diabetes Mellitus: Inflammation, Oxidative Stress, and Mitochondrial Function

  2016cites this paper
• From Animal Models to Clinical Practicality: Lessons Learned from Current Translational Progress of Diabetic Peripheral Neuropathy

  2013cites this paper
• Aldose reductase, still a compelling target for diabetic neuropathy.

  2008cites this paper
• Diabetic neuropathy: mechanisms to management.

  2008cites this paper
• Characterization of Binding Pocket Flexibility of Aldose Reductase

  2006cites this paper
• Clinical Potential of Aldose Reductase Inhibitors in Diabetic Neuropathy

  2004cites this paper
• Diabetic neuropathy and nerve regeneration.

  2003cites this paper
• The pharmacology of diabetic complications.

  2003cites this paper
• Recent advances in aldose reductase inhibitors: potential agents for the treatment of diabetic complications

  2002cites this paper
• Abnormal axonal inward rectifier in streptozocin-induced experimental diabetic neuropathy.

  2001cites this paper
• Pharmacological approaches to the treatment of diabetic complications

  2000cites this paper
• In vitro inhibition of glucose phosphorylation by an aldose-reductase inhibitor (Tolrestat) in some non-insulin-sensitive rabbit tissues.

  1999cites this paper
• Progression rates of diabetic neuropathy in placebo patients in an 18-month clinical trial. Ponalrestat Study Group.

  1998cites this paper
• Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications.

  1998cites this paper
• Aldose Reductase Inhibitors: The End of an Era or the Need for Different Trial Designs?

  1997cites this paper
• The Efficacy of Aldose Reductase Inhibitors in the Management of Diabetic Complications

  1995cites this paper
• Biochemical and vascular factors in the pathogenesis of diabetic neuropathy.

  1995cites this paper
• The efficacy of aldose reductase inhibitors in the management of diabetic complications. Comparison with intensive insulin treatment and pancreatic transplantation.

  1995cites this paper